127 related articles for article (PubMed ID: 19888257)
1. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case.
Mocciaro F; Renna S; Orlando A; Cottone M
Am J Gastroenterol; 2009 Nov; 104(11):2867-8. PubMed ID: 19888257
[No Abstract] [Full Text] [Related]
2. Psoriatic skin lesions induced by certolizumab pegol.
Klein RQ; Spivack J; Choate KA
Arch Dermatol; 2010 Sep; 146(9):1055-6. PubMed ID: 20855720
[No Abstract] [Full Text] [Related]
3. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
5. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
Lazebnik LB; Kniazev OV
Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
[No Abstract] [Full Text] [Related]
6. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab (Cimzia) for Crohn's disease.
Med Lett Drugs Ther; 2008 Oct; 50(1297):81-2. PubMed ID: 18927521
[No Abstract] [Full Text] [Related]
8. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Lichtenstein GR; Thomsen OØ; Schreiber S; Lawrance IC; Hanauer SB; Bloomfield R; Sandborn WJ;
Clin Gastroenterol Hepatol; 2010 Jul; 8(7):600-9. PubMed ID: 20117244
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab pegol for the treatment of Crohn's disease.
Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
[TBL] [Abstract][Full Text] [Related]
10. A case report of nephrotic syndrome due to intake of certolizumab pegol in a patient with Crohn's disease.
Leong J; Fung-Liu B
Am J Gastroenterol; 2010 Jan; 105(1):234. PubMed ID: 20054326
[No Abstract] [Full Text] [Related]
11. Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.
Augustine JM; Lee JK; Armstrong EP
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):599-609. PubMed ID: 25209304
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
13. Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease.
Mocciaro F; Orlando A; Renna S; Rizzuto MR; Cottone M
J Crohns Colitis; 2011 Apr; 5(2):173-4. PubMed ID: 21453892
[No Abstract] [Full Text] [Related]
14. Meningococcal meningoencephalitis after certolizumab pegol treatment in a patient with Crohn's disease.
Majumder S; Kumar A
J Crohns Colitis; 2013 Feb; 7(1):e19. PubMed ID: 22742971
[No Abstract] [Full Text] [Related]
15. Drug approvals: '08 in review. Certolizumab pegol (Cimzia).
Laustsen G; Carrillo F; Johnson J; Smith C
Nurse Pract; 2009 Feb; 34(2):26-7. PubMed ID: 19155878
[No Abstract] [Full Text] [Related]
16. Another anti-TNF therapy for patients with Crohn's disease.
Cross R
Inflamm Bowel Dis; 2008 Mar; 14(3):425-7. PubMed ID: 18095318
[No Abstract] [Full Text] [Related]
17. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
Feagan BG; Reilly MC; Gerlier L; Brabant Y; Brown M; Schreiber S
Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
Feagan BG; Sandborn WJ; Wolf DC; Coteur G; Purcaru O; Brabant Y; Rutgeerts PJ
Aliment Pharmacol Ther; 2011 Mar; 33(5):541-50. PubMed ID: 21223344
[TBL] [Abstract][Full Text] [Related]
19. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
Sandborn WJ; Schreiber S; Hanauer SB; Colombel JF; Bloomfield R; Lichtenstein GR;
Clin Gastroenterol Hepatol; 2010 Aug; 8(8):696-702.e1. PubMed ID: 20363366
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
Schreiber S; Lawrance IC; Thomsen OØ; Hanauer SB; Bloomfield R; Sandborn WJ
Aliment Pharmacol Ther; 2011 Jan; 33(2):185-93. PubMed ID: 21083671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
